Fundz
New|Fundz now works inside Claude2 min

AI made execution free. Knowing first is the whole game now.

The advantage goes to whoever is first into the right conversations, most often. Fundz stacks those odds: more of the moments that create demand than anyone else catches, as they happen, matched to who you sell to, with the decision maker to call. Now it answers in Claude too: ask for today’s leads and who to reach, then write the note in the same window. Not a feed. Not a list you rent. A system for being first.

Trusted by

OracleSnowflakeCloudflareLinkedInGoogleSalesforce
4.8/5 on G2· Since 2015

Kasvu Therapeutics has raised €30 million in a Series A financing round led by Hadean Ventures. The funding will advance its novel TrkB potentiator into clinical development targeting neuropsychiatric disorders.

PRIVATESep 24, 2026•about 4 hours ago

Amount Raised

€30 Million

Round Type

Series A

HelsinkiBiotechnologyHealth CareTherapeutics

Investors

Helsinki University FundsNordic Science InvestmentsStephen IndustriesFinnish Drug Discovery CenterInnovestor Life Science FundTesiHadean Ventures

Description

Kasvu Therapeutics, a company focused on developing neuroplastogens, announced its €30 million Series A financing round. The round was led by Hadean Ventures with participation from various investors including Tesi and Innovestor Life Science Fund. The funds will aid in advancing its lead candidate KTX-0141 through clinical development. Clinical trials are anticipated to start in the latter half of 2027.

Company Information

Company

Kasvu Therapeutics

Location

Helsinki, Uusimaa, Finland

About

Kasvu Therapeutics is developing a new generation of neuroplastogens for neuropsychiatric and neurodegenerative disorders. The company focuses on a novel class of small-molecule potentiators designed to enhance neuroplasticity pathways without inducing hallucinogenic effects. Their lead candidate, KTX-0141, selectively amplifies BDNF signaling to potentially treat major depressive disorder and other mental health conditions. Kasvu aims to provide rapid-acting and long-lasting treatment options for patients.

Fundz sees it the moment Kasvu Therapeutics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Predictive Intelligence
Strategic

ML-powered predictions for Kasvu Therapeutics's next move

See what Strategic adds

Funding Insights

What this usually means
Typical timeline to Series B
Series A companies typically raise their next round in 10-18 months

Kasvu Therapeutics raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick. $29 a month, billed annually, and if it does not pay for itself in a year we refund it.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 285,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.